Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominika Wranik

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Health Economics, Policy, and Law|December 14, 2011
Healthcare policy tools as determinants of health-system efficiency: evidence from the OECDDominika Wranik
Health Policy (Amsterdam, Netherlands)|October 13, 2007
Health human resource planning in Canada: a typology and its applicationDominika Wranik
Social Work in Public Health|May 3, 2011
Framework for the design of physician remuneration methods in primary health careDominika Wranik, Martine Durier-Copp
Pharmacoeconomics|January 22, 2018
The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017Chris Skedgel, Dominika Wranik, Min Hu
Human Resources for Health|August 15, 2018
Funding models and medical dominance in interdisciplinary primary care teams: qualitative evidence from three Canadian provincesWiesława Dominika Wranik, Susan Marie Haydt
Expert Review of Pharmacoeconomics & Outcomes Research|September 1, 2018
Drug attributes associated with the selection of drugs for reimbursement: a pilot stated preferences experiment with Canadian stakeholdersWiesława Dominika Wranik, Christopher Skedgel, Min Hu
Health Economics Review|February 12, 2017
Costs of productivity loss due to occupational cancer in Canada: estimation using claims data from Workers' Compensation BoardsW Dominika Wranik, Adam Muir, Min Hu
Health Policy (Amsterdam, Netherlands)|January 3, 2021
Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and PolandWiesława Dominika Wranik, Liesl Gambold, Stuart Peacock
Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale|September 16, 2014
Physician payment methods: a focus on quality and cost controlLuke Rudmik, Dominika Wranik, Caroline Rudisill-Michaelsen
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 25, 2020
Ranking the Criteria Used in the Appraisal of Drugs for Reimbursement: A Stated Preferences Elicitation With Health Technology Assessment Stakeholders Across Jurisdictional ContextsWiesława Dominika Wranik, Michał Jakubczyk, Krzysztof Drachal
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Health Economics, Policy, and Law|December 14, 2011
Healthcare policy tools as determinants of health-system efficiency: evidence from the OECDDominika Wranik
Health Policy (Amsterdam, Netherlands)|October 13, 2007
Health human resource planning in Canada: a typology and its applicationDominika Wranik
Social Work in Public Health|May 3, 2011
Framework for the design of physician remuneration methods in primary health careDominika Wranik, Martine Durier-Copp
Pharmacoeconomics|January 22, 2018
The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017Chris Skedgel, Dominika Wranik, Min Hu
Human Resources for Health|August 15, 2018
Funding models and medical dominance in interdisciplinary primary care teams: qualitative evidence from three Canadian provincesWiesława Dominika Wranik, Susan Marie Haydt
Expert Review of Pharmacoeconomics & Outcomes Research|September 1, 2018
Drug attributes associated with the selection of drugs for reimbursement: a pilot stated preferences experiment with Canadian stakeholdersWiesława Dominika Wranik, Christopher Skedgel, Min Hu
Health Economics Review|February 12, 2017
Costs of productivity loss due to occupational cancer in Canada: estimation using claims data from Workers' Compensation BoardsW Dominika Wranik, Adam Muir, Min Hu
Health Policy (Amsterdam, Netherlands)|January 3, 2021
Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and PolandWiesława Dominika Wranik, Liesl Gambold, Stuart Peacock
Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale|September 16, 2014
Physician payment methods: a focus on quality and cost controlLuke Rudmik, Dominika Wranik, Caroline Rudisill-Michaelsen
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 25, 2020
Ranking the Criteria Used in the Appraisal of Drugs for Reimbursement: A Stated Preferences Elicitation With Health Technology Assessment Stakeholders Across Jurisdictional ContextsWiesława Dominika Wranik, Michał Jakubczyk, Krzysztof Drachal
Pageof 3